Dynavax Technologies Corp (DVAX)

20.50
NASDAQ : Health Care
Prev Close 20.80
Day Low/High 20.25 / 21.00
52 Wk Low/High 3.20 / 21.85
Avg Volume 2.81M
Exchange NASDAQ
Shares Outstanding 60.50M
Market Cap 1.26B
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

Small-Cap Turnaround Stories

Small-Cap Turnaround Stories

When one of these pays off, it can make up for a number of errant wagers.

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Jim Cramer says investors should step away from these near-term shenanigans and focus on the fundamentals.

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

Jim Cramer is bullish on Chevron, Universal Display, Dynavax Technologies, and Schlumberger.

Dow's Big Day Ends With Record and Best Monthly Gain Since February

Dow's Big Day Ends With Record and Best Monthly Gain Since February

The Dow ends July with a bang.

Dow at Records, Rest of Market Retreats, in Close to Strong July

Dow at Records, Rest of Market Retreats, in Close to Strong July

Stocks are mixed.

The Stock Market Looks Like It Could End July With a Bang

The Stock Market Looks Like It Could End July With a Bang

Stock futures are higher.

Navigate Choppy Investment Waters With Good Trade Management

Navigate Choppy Investment Waters With Good Trade Management

The inconsistency makes stock picking difficult, but there are buying opportunities because of it.

September 15th Options Now Available For Dynavax Technologies (DVAX)

Investors in Dynavax Technologies Corp saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DVAX options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

Interesting DVAX Call Options For July 21st

Investors in Dynavax Technologies Corp saw new options become available this week, for the July 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DVAX options chain for the new July 21st contracts and identified the following call contract of particular interest.

3 Biotech Stocks on Readers' Minds

3 Biotech Stocks on Readers' Minds

We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.

3 Small Biotechs on the FDA Summer Calendar

3 Small Biotechs on the FDA Summer Calendar

Dynavax Technologies, Ocular Therapeutix and Neos Therapeutics have big drug approval dates ahead.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and...

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

Commit To Purchase Dynavax Technologies Corp At $6, Earn 78.3% Annualized Using Options

Investors eyeing a purchase of Dynavax Technologies Corp stock, but cautious about paying the going market price of $6.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $6 strike, which has a bid at the time of this writing of $1.75.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

2 Questions From the Biotech Mailbag

2 Questions From the Biotech Mailbag

A look at how lawsuits and FDA changes could impact the industry.

Short Interest Decreases By 14.2% For DVAX

The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 1,200,260 share decrease in total short interest for Dynavax Technologies Corp , to 7,245,226, a decrease of 14.21% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - DVAX

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Dynavax Technologies Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017 - DVAX

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Dynavax Technologies Corporation (NASDAQ: DVAX) between March...

DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017

DVAX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Dynavax Technologies Corporation And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation (NASDAQ:DVAX)...

TheStreet Quant Rating: D (Sell)